Literature DB >> 21423789

Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials.

Lingling Li1, Scott R Evans, Hajime Uno, L J Wei.   

Abstract

Group sequential designs are often used in clinical trials to evaluate efficacy and/or futility. Many methods have been developed for different types of endpoints and scenarios. However, few of these methods convey information regarding effect sizes (e.g., treatment differences) and none uses prediction to convey information regarding potential effect size estimates and associated precision, with trial continuation. To address these limitations, Evans et al. (2007) proposed to use prediction and predicted intervals as a flexible and practical tool for quantitative monitoring of clinical trials. In this article, we reaffirm the importance and usefulness of this innovative approach and introduce a graphical summary, predicted interval plots (PIPS), to display the information obtained in the prediction process in a straightforward yet comprehensive manner. We outline the construction of PIPS and apply this method in two examples. The results and the interpretations of the PIPS are discussed.

Entities:  

Year:  2009        PMID: 21423789      PMCID: PMC3059316          DOI: 10.1198/sbr.2009.0041

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  9 in total

1.  Forest plots: trying to see the wood and the trees.

Authors:  S Lewis; M Clarke
Journal:  BMJ       Date:  2001-06-16

2.  Monitoring a randomized clinical trial for futility: the north-Norwegian lidocaine intervention trial.

Authors:  R F Berntsen; K Rasmussen; J F Bjørnstad
Journal:  Stat Med       Date:  1991-03       Impact factor: 2.373

3.  Approximately optimal one-parameter boundaries for group sequential trials.

Authors:  S K Wang; A A Tsiatis
Journal:  Biometrics       Date:  1987-03       Impact factor: 2.571

4.  Repeated confidence intervals for group sequential clinical trials.

Authors:  C Jennison; B W Turnbull
Journal:  Control Clin Trials       Date:  1984-03

5.  Group sequential clinical trials with triangular continuation regions.

Authors:  J Whitehead; I Stratton
Journal:  Biometrics       Date:  1983-03       Impact factor: 2.571

6.  Early decision in clinical trials when the treatment differences are small. Experience of a controlled trial in head trauma.

Authors:  S C Choi; P J Smith; D P Becker
Journal:  Control Clin Trials       Date:  1985-12

7.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

8.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

9.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

  9 in total
  8 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  Clinical trial structures.

Authors:  Scott R Evans
Journal:  J Exp Stroke Transl Med       Date:  2010-02-09

Review 3.  Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research.

Authors:  W Charles Huskins; Vance G Fowler; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

Review 4.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

5.  Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.

Authors:  Jacqueline Huvane; Lauren Komarow; Carol Hill; Thuy Tien T Tran; Carol Pereira; Susan L Rosenkranz; Matt Finnemeyer; Michelle Earley; Hongyu Jeanne Jiang; Rui Wang; Judith Lok; Scott R Evans
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

6.  Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.

Authors:  Nicholas A Turner; Smitha Zaharoff; Heather King; Scott Evans; Toshimitsu Hamasaki; Thomas Lodise; Varduhi Ghazaryan; Tatiana Beresnev; Todd Riccobene; Rinal Patel; Sarah B Doernberg; Urania Rappo; Vance G Fowler; Thomas L Holland
Journal:  Trials       Date:  2022-05-16       Impact factor: 2.728

7.  Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction.

Authors:  Koko Asakura; Scott R Evans; Toshimitsu Hamasaki
Journal:  Stat Biopharm Res       Date:  2019-11-04       Impact factor: 1.452

8.  Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone: Reports of a Randomised Trial From The Japan Working Group for the Assessment Whether Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study).

Authors:  Masanori Asakura; Jiyoong Kim; Hiroshi Asanuma; Yasuharu Nakama; Kengo Tsukahara; Yorihiko Higashino; Tetsuya Ishikawa; Shinji Koba; Mitsuru Tsujimoto; Hideo Himeno; Yasuyuki Maruyama; Takanori Ookusa; Shunichi Yoda; Hiroshi Suzuki; Shinji Okubo; Makoto Shimizu; Yuji Hashimoto; Kazuo Satake; Susumu Fujino; Hiroyasu Uzui; Yoshiyuki Nagai; Tohru Kohno; Sumio Mizuno; Makoto Nakahama; Hounin Kanaya; Toyoaki Murohara; Kazuki Fukui; Hiroyuki Takase; Nobuyuki Ohte; Takaaki Shiono; Masatake Fukunami; Tsutomu Endo; Reimin Sawada; Kenshi Fujii; Motoshi Takeuchi; Shuntaro Ikeda; Koichi Mizuno; Masaaki Uematsu; Taku Matsubara; Shoji Yano; Jun Takahashi; Kousei Ueda; Yoshihiko Kinoshita; Koichi Tamita; Hideki Hayashi; Toshimitsu Hamasaki; Masafumi Kitakaze
Journal:  EClinicalMedicine       Date:  2018-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.